Earnings Call · Q3 FY2025·2025-11-13

Q3 25EPS -100.00%*·Rev n/aQ2 25EPS -20.00%·Rev n/aQ1 25EPS -87.10%·Rev n/aQ4 24EPS +11.43%·Rev n/a⚠ consensus missing

RELMADA THERAPEUTICS, INC. RLMD

Brian Ritchie — Investor Relations or Communications Officer

Sergio Traversa — Chief Executive Officer

Raj S. Pruthi — Head of Clinical Program

Maged S. Shenouda — Chief Financial Officer or Financial Officer

−0.8%1d on move date+0.9% vs SPY3d+1.5%5d+6.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RLMD calls or request research access.

More RLMD calls Browse calls Request research access